Trial Profile
In search for an innovative neural marker and intervention for socio-communicative difficulties in children with and without autism spectrum disorders
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 13 Oct 2021
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- Acronyms MOX
- 10 Oct 2021 Status changed from recruiting to completed.
- 06 Oct 2018 Status changed from not stated to recruiting.
- 10 Jul 2018 New trial record